Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product pipeline consists of a […]
Krystal Biotech (NASDAQ:KRYS – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Volatility & Risk Krystal Biotech has a beta of […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Wall Street brokerages expect Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) to report earnings of ($0.23) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Cardiff Oncology’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Cardiff Oncology reported earnings of […]
Equities research analysts predict that Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) will announce $80,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cardiff Oncology’s earnings, with estimates ranging from $50,000.00 to $100,000.00. Cardiff Oncology posted sales of $70,000.00 during the same quarter last year, which suggests […]